We are live on !
Find out more
Foundry Partners Portfolio holdings
AUM
$1.89B
Turnover
15.38%
1-Year Est. Return
9.84%
This Fund
S&P 500
This Quarter Est. Return
-3.32%
1 Year Est. Return
+9.84%
3 Year Est. Return
+44.42%
5 Year Est. Return
+233.05%
10 Year Est. Return
+297.72%
AUM
$1.59B
AUM Growth
-$73.3M
(-4.4%)
Cap. Flow
+$12.5M
Cap. Flow % of AUM
Cap. Flow %
0.79%
Top 10 Holdings %
Top 10 Hldgs %
19.06%
Holding
339
New
37
Increased
202
Reduced
75
Closed
23
Avg Time Held
2.8
years
Top 10 Avg Time Held
1.2
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$21.8M |
| 2 |
BorgWarner
BWA
|
+$18.9M |
| 3 |
Hartford Financial Services
HIG
|
+$18.6M |
| 4 |
Cigna
CI
|
+$15.3M |
| 5 |
Fox Class A
FOXA
|
+$11.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$25.5M |
| 2 |
Centene
CNC
|
+$18.6M |
| 3 |
Qualcomm
QCOM
|
+$13.2M |
| 4 |
Ally Financial
ALLY
|
+$11.4M |
| 5 |
Verizon
VZ
|
+$10.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 23.2% |
| 2 | Healthcare | 13.26% |
| 3 | Industrials | 12.11% |
| 4 | Energy | 9.68% |
| 5 | Technology | 9.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
JPMorgan Chase
JPM
$914B
| $37.1M | 2.34% |
354,946
+49,025
| +16% | +$5.63M |
2014 Q4
31 quarters
|
|
2
Johnson & Johnson
JNJ
$689B
| $36.6M | 2.3% |
223,970
-33,220
| -13% | -$5.62M |
2021 Q1
6 quarters
|
|
3
Merck
MRK
$361B
| $34.2M | 2.15% |
396,875
-49,090
| -11% | -$4.38M |
2022 Q1
2 quarters
|
|
4
ConocoPhillips
COP
$167B
| $31.6M | 1.99% |
309,260
+2,465
| +0.8% | +$246K |
2021 Q2
5 quarters
|
|
5
AES
AES
$10.7B
| $30.6M | 1.93% |
1,354,652
+56,225
| +4% | +$1.33M |
2019 Q3
12 quarters
|
|
6
Altria Group
MO
$131B
| $29.2M | 1.84% |
722,318
+129,200
| +22% | +$5.64M |
2019 Q3
12 quarters
|
|
7
CVS Health
CVS
$113B
| $28.9M | 1.82% |
303,177
+55,860
| +23% | +$5.53M |
2013 Q4
35 quarters
|
|
8
Elevance Health
ELV
$91.2B
| $25.5M | 1.61% |
56,177
+425
| +0.8% | +$203K |
2020 Q2
9 quarters
|
|
9
Shell
SHEL
$279B
| $24.7M | 1.55% |
495,619
-52,375
| -10% | -$2.7M |
2022 Q1
2 quarters
|
|
10
Kroger
KR
$42B
| $24.3M | 1.53% |
554,501
-2,190
| -0.4% | -$104K |
2018 Q1
18 quarters
|
|
11
Huntington Bancshares
HBAN
$31.8B
| $24.2M | 1.52% |
1,832,840
+211,595
| +13% | +$2.83M |
2021 Q3
4 quarters
|
|
|
12
Verizon
VZ
$192B
| $23.8M | 1.5% |
625,822
-242,775
| -28% | -$10.8M |
2017 Q4
19 quarters
|
|
13
Caterpillar
CAT
$272B
| $21.9M | 1.38% |
133,257
+925
| +0.7% | +$169K |
2018 Q3
16 quarters
|
|
14
Exelon
EXC
$47.8B
| $21.7M | 1.37% |
580,085
+15,565
| +3% | +$688K |
2021 Q3
4 quarters
|
|
15
Ameriprise Financial
AMP
$44.8B
| $21.6M | 1.36% |
85,862
+715
| +0.8% | +$188K |
2013 Q4
35 quarters
|
|
|
16
Gilead Sciences
GILD
$209B
| $21.3M | 1.34% |
+345,955
| New | +$21.8M |
2022 Q3
0 quarters
|
|
17
Prudential Financial
PRU
$42B
| $21.3M | 1.34% |
248,710
+18,260
| +8% | +$1.76M |
2013 Q4
35 quarters
|
|
18
Huntington Ingalls Industries
HII
$12B
| $20.7M | 1.31% |
93,630
+10,540
| +13% | +$2.36M |
2022 Q2
1 quarter
|
|
19
Comcast
CMCSA
$89.7B
| $19.6M | 1.23% |
667,735
+5,425
| +0.8% | +$203K |
2021 Q3
4 quarters
|
|
20
Goldman Sachs
GS
$262B
| $19.3M | 1.22% |
66,002
-19,922
| -23% | -$6.45M |
2013 Q4
35 quarters
|
|
21
Emerson Electric
EMR
$90.8B
| $18.9M | 1.19% |
257,570
+52,650
| +26% | +$4.37M |
2021 Q4
3 quarters
|
|
|
22
Hartford Financial Services
HIG
$36.9B
| $17.7M | 1.12% |
+286,050
| New | +$18.6M |
2022 Q3
0 quarters
|
|
23
EOG Resources
EOG
$81.4B
| $17.7M | 1.11% |
158,425
-24,980
| -14% | -$2.8M |
2020 Q4
7 quarters
|
|
24
Simon Property Group
SPG
$75.4B
| $17.7M | 1.11% |
196,685
+32,755
| +20% | +$3.35M |
2021 Q2
5 quarters
|
|
25
LKQ Corp
LKQ
$4.91B
| $16.8M | 1.06% |
355,565
-18,720
| -5% | -$979K |
2022 Q2
1 quarter
|
|
Similar funds
PAME
Foundry Partners's Q3 2022 Portfolio in Review
As of Q3 2022, Foundry Partners held 339 positions worth $1.59B, down 4.4% from $1.66B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Foundry Partners's Q3 2022 filing shows 37 new, 202 increased, 75 reduced and 23 closed positions. Its largest new stake was Gilead Sciences: 345,955 shares worth $21.3M. The largest sale was Pfizer, an estimated $25.5M.
By sector, the portfolio is most concentrated in Financials at 23% of assets, up from 22% a quarter earlier, followed by Healthcare and Industrials.
- Foundry Partners's largest Q3 2022 buy was Gilead Sciences: 345,955 shares worth $21.3M.
- Foundry Partners added most to Altria Group in Q3 2022, an estimated $5.64M increase.
- Foundry Partners's biggest Q3 2022 reduction was Verizon, cutting an estimated $10.8M.
- Foundry Partners fully exited Pfizer in Q3 2022, selling an estimated $25.5M.
- Foundry Partners's ten largest holdings make up 19% of its $1.59B portfolio in Q3 2022.
- Foundry Partners opened 37 new positions and closed 23 in Q3 2022.
- Foundry Partners's portfolio value fell 4.4% quarter-over-quarter to $1.59B.
Based on Foundry Partners's 13F filing for Q3 2022, filed 21 Oct 2022.